{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:55:45Z","timestamp":1790621745250,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been associated with multiple entities and several types of cancers. They can be assumed as markers of inflammatory imbalance. The objective of this study is to evaluate the NLR and PLR in Peyronie's disease (PD) and to establish a comparison of its values in the acute and chronic stages. We recruited patients with PD from March 2018 to March 2019. The patients enrolled underwent medical and sexual history as well as a physical examination. The values of blood count of each patient were collected both in the acute and chronic stages. Wilcoxon test was used to compare the acute and chronic stage ratios. Kruskal\u2013Wallis test was carried out to evaluate the impact of treatments on the ratios. To identify cutoff values, we used sensibility and specificity tables and receiver operating characteristic (ROC) curves. A total of 120 patients were enrolled. Their mean age was 55.85 (range: 18\u201377) years and the mean penile curvature was 48.43\u00b0 (range: 10\u00b0\u2013100\u00b0). In the acute stage, the mean NLR was 2.35 and the mean PLR was 111.22. These ratios, in the chronic stage, were 1.57 and 100.00, respectively. Statistically significant differences between acute and stable stages for both indices were found (NLR:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001; PLR:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0202). The optimal cutoff for classification in acute or stable stage was 2 for NLR and 102 for PLR. According to our results, with an ordinary blood count, we could have important indications regarding the disease stage of the patient, and consequently on the most appropriate type of therapy to choose.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aja.aja_74_20","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T02:55:36Z","timestamp":1608605736000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Role of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in Peyronie's disease"],"prefix":"10.4103","volume":"23","author":[{"given":"Esther Garc\u00eda","family":"Rojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja Garc\u00eda","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio Santos-P\u00e9rez","family":"de la Blanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Alonso","family":"Isa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Medina","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Rodr\u00edguez","family":"Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Romero","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20240829","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"17","author":"Al-Thakafi","year":"2016","journal-title":"Transl Androl Urol"},{"key":"R2-16-20240829","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1743-6109.2009.01584.x","article-title":"A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease","volume":"7","author":"Rhoden","year":"2010","journal-title":"J Sex Med"},{"key":"R3-16-20240829","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.aju.2013.06.006","article-title":"The pathophysiology of Peyronie's disease","volume":"11","author":"El-Sakka","year":"2013","journal-title":"Arab J Urol"},{"key":"R4-16-20240829","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.aju.2013.03.008","article-title":"Peyronie's disease: a contemporary review of non-surgical treatment","volume":"11","author":"Levine","year":"2013","journal-title":"Arab J Urol"},{"key":"R5-16-20240829","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eururo.2006.10.042","article-title":"Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease","volume":"51","author":"Russell","year":"2007","journal-title":"Eur Urol"},{"key":"R6-16-20240829","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/andr.12058","article-title":"Therapeutic advances in the treatment of Peyronie's disease","volume":"3","author":"Yafi","year":"2015","journal-title":"Andrology"},{"key":"R7-16-20240829","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.eururo.2006.10.048","article-title":"Seeking answers on the quest for effective nonsurgical treatment of Peyronie's disease","volume":"51","author":"Levine","year":"2007","journal-title":"Eur Urol"},{"key":"R8-16-20240829","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.sxmr.2017.07.005","article-title":"Collagenase clostridium histolyticum in the treatment of Peyronie's disease \u2013 a review of the literature and a new modified protocol","volume":"5","author":"Abdel Raheem","year":"2017","journal-title":"Sex Med Rev"},{"key":"R9-16-20240829","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"R10-16-20240829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urology.2020.07.048","article-title":"Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis","volume":"145","author":"Nguyen","year":"2020","journal-title":"Urology"},{"key":"R11-16-20240829","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40261-020-00916-4","article-title":"Efficacy of collagenase clostridium histolyticum (Xiapex\u00ae) in patients with the acute phase of Peyronie's disease","volume":"40","author":"Cocci","year":"2020","journal-title":"Clin Drug Investig"},{"key":"R12-16-20240829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/asheducation-2011.1.51","article-title":"The role of platelets in atherothrombosis","volume":"2011","author":"Kaplan","year":"2011","journal-title":"Hematology"},{"key":"R13-16-20240829","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCRESAHA.111.257535","article-title":"Multiple roles for neutrophils in atherosclerosis","volume":"110","author":"Soehnlein","year":"2012","journal-title":"Circ Res"},{"key":"R14-16-20240829","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/10739680802651477","article-title":"Platelet adhesion under flow","volume":"16","author":"Ruggeri","year":"2009","journal-title":"Microcirculation"},{"key":"R15-16-20240829","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R16-16-20240829","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/14779072.2016.1154788","article-title":"Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update","volume":"14","author":"Afari","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R17-16-20240829","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/1756-185X.13400","article-title":"Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab","volume":"21","author":"Sargin","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R18-16-20240829","first-page":"63","article-title":"[Utility of the neutrophil\/lymphocyte ratio and the polymorphonuclear\/monomorphonuclear ratio, in the prediction of preeclampsia]","volume":"36","author":"Ghelfi","year":"2019","journal-title":"Hipertensi\u00f3n"},{"key":"R19-16-20240829","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil\u2013lymphocyte ratio: experience in patients with cancer","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R20-16-20240829","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3332\/ecancer.2016.702","article-title":"The neutrophil-to-lymphocyte ratio: a narrative review","volume":"10","author":"Socorro Faria","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"R21-16-20240829","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/andr.12702","article-title":"The role of inflammatory parameters (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-eosinophil ratio) in patients with Peyronie's disease","volume":"8","author":"\u00d6zbir","year":"2020","journal-title":"Andrologia"},{"key":"R22-16-20240829","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000280897","article-title":"Classification of congenital and acquired penile deviation","volume":"38","author":"Kel\u00e2mi","year":"1983","journal-title":"Urol Int"},{"key":"R23-16-20240829","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"R24-16-20240829","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1464-410X.2006.05969.x","article-title":"Risk factors for Peyronie's disease: a case-control study","volume":"97","author":"Bjekic","year":"2006","journal-title":"BJU Int"},{"key":"R25-16-20240829","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0022-5347(01)65364-3","article-title":"Cellular and biochemical aspects of normal and abnormal wound healing: an overview","volume":"157","author":"Diegelmann","year":"1997","journal-title":"J Urol"},{"key":"R26-16-20240829","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J Urol"},{"key":"R27-16-20240829","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","article-title":"Expanding the paradigm for plaque development in Peyronie's disease","volume":"15","author":"Mulhall","year":"2003","journal-title":"Int J Impot Res"},{"key":"R28-16-20240829","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"5","author":"Al-Thakafi","year":"2016","journal-title":"Transl Androl Urol"},{"key":"R29-16-20240829","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0014-5793(88)80580-5","article-title":"Transforming growth factor \u03b2 regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts","volume":"228","author":"Balza","year":"1988","journal-title":"FEBS Letters"},{"key":"R30-16-20240829","doi-asserted-by":"crossref","first-page":"e11138","DOI":"10.1097\/MD.0000000000011138","article-title":"Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_74_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:58Z","timestamp":1786735858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_74_20"}},"subtitle":["a new diagnostic approach to predict the stage of the disease?"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/aja.aja_74_20","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}